首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1907951

神經精神治療市場：按疾病、藥物類別、給藥途徑、劑型、患者年齡層、醫療機構、醫療服務提供者類型、分銷管道、支付方式和地區分類

Neuropsychiatric Disorders Treatment Market, By Disorder, By Drug Class, By Route of Administration, By Formulation Type, By Patient Age Group, By Care Setting, By Provider Type, By Distribution Channel, By Payment Type, By Geography

出版日期: 2025年12月23日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2025 年，神經精神治療市場規模將達到 762.1 億美元，到 2032 年將達到 1,016.4 億美元，2025 年至 2032 年的複合年成長率為 4.2%。

分析範圍		分析詳情
基準年	2024	市場規模（2025 年）	762.1億美元
效能數據	2020-2024	預測期	2025-2032
預測期（2025-2032 年）複合年成長率	4.20%	預計金額（2032 年）	1016.4億美元

全球神經精神治療市場在更廣泛的醫療保健領域中佔據著重要地位，涵蓋了影響神經和精神功能的複雜疾病的治療性介入。

神經精神疾病涵蓋範圍廣泛，包括憂鬱症、焦慮症、躁鬱症、思覺失調症、注意力不足過動症（ADHD）、泛自閉症障礙以及阿茲海默症和帕金森氏症等神經退化性疾病。這些疾病對患者的認知、情緒和行為有顯著影響，並給全球醫療保健帶來沉重負擔。

治療市場涵蓋多種治療方法，包括藥物療法、心理療法、神經刺激技術以及新興創新治療方法，例如數位療法和精準醫療。由於人口老化、生活方式改變、壓力增加以及診斷能力提高等因素，全球神經精神疾病的盛行率不斷上升，從而推動了對有效治療方案的需求。

鑑於這些疾病對經濟和社會的重大影響，世界各地的醫療衛生系統正在增加對新治療方法研發的投入。市場以持續創新為特徵，製藥、生技和醫療設備公司正積極開發下一代治療方法，以期提高療效、減少副作用並提供個人化治療通訊協定，從而應對神經精神疾病的複雜性和多樣性。

市場動態

全球神經精神疾病治療市場受多種關鍵因素驅動，這些因素正在從根本上改變治療格局。其中一個關鍵促進因素是全球神經精神疾病盛行率的不斷上升。根據世界衛生組織（世衛組織）報告，全球有超過9.7億人患有精神疾病，而隨著人口老化，神經退化性疾病也持續上升。

人們對心理健康的認知不斷提高，對心理健康的歧視也逐漸減少，這提高了診斷率和就醫意願，顯著擴大了患者群體。藥物研發技術的進步，包括人工智慧輔助的監測、生物標記識別和個人化醫療方法，正在加速開發更具針對性和更有效的治療方法。

政府措施和增加對精神衛生服務的醫療保健支出，尤其是在疫情之後，創造了有利的法規環境和資金籌措機會。然而，市場面臨許多限制因素，包括高成本和漫長的核准流程（可能耗時10-15年，耗資數十億美元）。由於神經精神藥物的作用機制複雜且可能存在副作用，因此受到嚴格的監管要求，這進一步阻礙了其市場准入。這些疾病的異質性使得治療標準化變得困難，而治療抗藥性、用藥依從性以及對複雜腦機制缺乏了解等挑戰，仍然阻礙著相關領域的進展。

儘管面臨諸多挑戰，新興市場仍蘊藏著巨大的機遇，這得益於醫療基礎建設的完善和心理健康意識提升的提升。數位療法、遠端醫療和人工智慧診斷工具的融合，為市場拓展開闢了新的途徑。對早期療育、預防性護理和聯合治療的日益重視，預示著市場成長的潛力；同時，新型藥物遞送系統和針對難治性疾病的突破性治療方法的研發，也為那些能夠滿足這些關鍵未滿足需求的創新型企業帶來了巨大的商業性機會。

本報告的主要特點

本報告對全球神經精神治療市場進行了詳細分析，並給出了預測期（2025-2032 年）的市場規模和複合年成長率，以 2024 年為基準年。
它還重點介紹了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
它還提供了有關市場促進因素、限制因素和機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的關鍵見解。
根據公司概況、產品系列、主要亮點、財務表現和策略等參數，對全球神經精神治療市場的主要企業進行了分析。
本報告提供的見解將使負責人和公司經營團隊能夠就未來的產品發布、產品更新、市場擴張和行銷策略做出明智的決策。
《全球神經精神疾病治療市場》報告面向該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過各種策略矩陣更輕鬆地分析全球神經精神疾病治療市場，從而做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東地區
非洲
- 南非
- 北非
- 中非

第15章競爭格局

Johnson and Johnson
Pfizer Inc
Roche Holding AG
Novartis AG
Eli Lilly and Company
Bristol-Myers Squibb Company
AstraZeneca PLC
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Otsuka Holdings Co Ltd
Lundbeck A/S
AbbVie Inc（including Allergan）
Biogen Inc
Teva Pharmaceutical Industries Ltd
Janssen Pharmaceutical Companies

第16章分析師建議

機會
分析師觀點
Coherent Opportunity Map (COM)

第17章參考文獻與分析方法

參考
分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI9127

Neuropsychiatric Disorders Treatment Market is estimated to be valued at USD 76.21 Bn in 2025 and is expected to reach USD 101.64 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.2% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 76.21 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	4.20%	2032 Value Projection:	USD 101.64 Bn

The global neuropsychiatric disorders treatment market represents a critical segment within the broader healthcare landscape, encompassing therapeutic interventions for complex conditions that affect both neurological and psychiatric functions.

Neuropsychiatric disorders include a diverse range of conditions such as depression, anxiety, bipolar disorder, schizophrenia, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, and neurodegenerative diseases like Alzheimer's and Parkinson's disease. These conditions significantly impact patients' cognitive, emotional, and behavioral functioning, creating substantial healthcare burdens worldwide.

The treatment market encompasses various therapeutic modalities including pharmacological interventions, psychotherapy, neurostimulation techniques, and emerging innovative therapies such as digital therapeutics and precision medicine approaches. The increasing prevalence of neuropsychiatric disorders globally, driven by factors such as aging populations, lifestyle changes, increased stress levels, and improved diagnostic capabilities, has intensified the demand for effective treatment solutions.

Healthcare systems worldwide are recognizing the substantial economic and social impact of these conditions, leading to increased investment in research and development of novel therapeutic approaches. The market is characterized by continuous innovation, with pharmaceutical companies, biotechnology firms, and medical device manufacturers actively developing next-generation treatments that promise improved efficacy, reduced side effects, and personalized treatment protocols to address the complex and heterogeneous nature of neuropsychiatric disorders.

Market Dynamics

The global neuropsychiatric disorders treatment market is propelled by several key drivers that are fundamentally reshaping the therapeutic landscape. The primary driver is the escalating global prevalence of neuropsychiatric conditions, with the World Health Organization reporting that mental health disorders affect over 970 million people worldwide, while neurodegenerative diseases continue to rise with aging populations.

Increased awareness and reduced stigma surrounding mental health have led to higher diagnosis rates and treatment-seeking behavior, substantially expanding the patient pool. Technological advancements in drug discovery, including artificial intelligence-driven research, biomarker identification, and personalized medicine approaches, are accelerating the development of more targeted and effective therapies.

Government initiatives and increased healthcare spending on mental health services, particularly post-pandemic, have created favorable regulatory environments and funding opportunities. However, the market faces significant restraints including the high cost of drug development and lengthy approval processes, which can span 10-15 years and cost billions of dollars. Stringent regulatory requirements for neuropsychiatric medications, given their complex mechanisms and potential side effects, create additional barriers to market entry. The heterogeneous nature of these disorders makes treatment standardization challenging, while issues such as treatment resistance, medication adherence, and limited understanding of complex brain mechanisms continue to impede progress.

Despite these challenges, substantial opportunities exist in emerging markets with improving healthcare infrastructure and increasing mental health awareness. The integration of digital therapeutics, telemedicine, and AI-powered diagnostic tools presents new avenues for market expansion. Growing focus on early intervention, preventive care, and combination therapies offers potential for market growth, while the development of novel drug delivery systems and breakthrough therapies for treatment-resistant conditions represents significant commercial opportunities for innovative companies positioned to address these critical unmet medical needs.

Key Features of the Study

This report provides in-depth analysis of the global neuropsychiatric disorders treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neuropsychiatric disorders treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Johnson and Johnson, Pfizer Inc, Roche Holding AG, Novartis AG, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Otsuka Holdings Co Ltd, H. Lundbeck A/S, AbbVie Inc (including Allergan), Biogen Inc, Teva Pharmaceutical Industries Ltd, and Janssen Pharmaceutical Companies
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global neuropsychiatric disorders treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuropsychiatric disorders treatment market

Market Segmentation

Disorder Insights (Revenue, USD Bn, 2020 - 2032)
- Major Depressive Disorder
- Bipolar Disorder
- Anxiety Disorders
- Schizophrenia Spectrum Disorders
- Trauma- and Stressor-Related Disorders
- Obsessive-Compulsive and Related Disorders
- Attention-Deficit/Hyperactivity Disorder
- Autism Spectrum Disorder
- Substance Use Disorders
- Sleep-Wake Disorders
- Neurocognitive Disorders
- Movement Disorders with psychiatric symptom control
- Eating Disorders
- Personality Disorders
Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Antidepressants
- Antipsychotics
- Mood Stabilizers
- Anxiolytics and Sedative-Hypnotics
- ADHD Medications
- Cognitive Enhancers
- Substance Use Disorder Medications
- Movement and Impulse Control Agents
- Adjunctive Symptom-Control Agents
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Intranasal
- Transdermal
- Sublingual or Buccal
Molecule Type Insights (Revenue, USD Bn, 2020 - 2032)
- Small molecules
- Biologics
- Combination drugs (fixed-dose combinations)
Formulation Type Insights (Revenue, USD Bn, 2020 - 2032)
- Immediate release
- Extended release or controlled release
- Long-acting depot formulations
- Orally disintegrating formulations
- Liquid oral formulations
- Prodrug formulations
Patient Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adolescent
- Adult/Geriatric
Care Setting Insights (Revenue, USD Bn, 2020 - 2032)
- Inpatient
- Outpatient
- Community-based Care
- Home-based Care
- Telehealth and Virtual Care
Provider Type Insights (Revenue, USD Bn, 2020 - 2032)
- Psychiatrists
- Neurologists
- Primary Care Physicians
- Psychologists and Therapists
- Addiction Medicine Specialists
- Integrated Care Teams
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Payment Type Insights (Revenue, USD Bn, 2020 - 2032)
- Public
- Private
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Johnson and Johnson
- Pfizer Inc
- Roche Holding AG
- Novartis AG
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Otsuka Holdings Co Ltd
- Lundbeck A/S
- AbbVie Inc (including Allergan)
- Biogen Inc
- Teva Pharmaceutical Industries Ltd
- Janssen Pharmaceutical Companies

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Neuropsychiatric Disorders Treatment Market, By Disorder
- Global Neuropsychiatric Disorders Treatment Market, By Drug Class
- Global Neuropsychiatric Disorders Treatment Market, By Route of Administration
- Global Neuropsychiatric Disorders Treatment Market, By Molecule Type
- Global Neuropsychiatric Disorders Treatment Market, By Formulation Type
- Global Neuropsychiatric Disorders Treatment Market, By Patient Age Group
- Global Neuropsychiatric Disorders Treatment Market, By Care Setting
- Global Neuropsychiatric Disorders Treatment Market, By Provider Type
- Global Neuropsychiatric Disorders Treatment Market, By Distribution Channel
- Global Neuropsychiatric Disorders Treatment Market, By Payment Type
- Global Neuropsychiatric Disorders Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Neuropsychiatric Disorders Treatment Market, By Disorder, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Major Depressive Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Anxiety Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Schizophrenia Spectrum Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Trauma- and Stressor-Related Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Obsessive-Compulsive and Related Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Attention-Deficit/Hyperactivity Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Autism Spectrum Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Substance Use Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Sleep-Wake Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Neurocognitive Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Movement Disorders with psychiatric symptom control
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Eating Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Personality Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Neuropsychiatric Disorders Treatment Market, By Drug Class, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Mood Stabilizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Anxiolytics and Sedative-Hypnotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
ADHD Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cognitive Enhancers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Substance Use Disorder Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Movement and Impulse Control Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Adjunctive Symptom-Control Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Neuropsychiatric Disorders Treatment Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Sublingual or Buccal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Neuropsychiatric Disorders Treatment Market, By Molecule Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Small molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Combination drugs (fixed-dose combinations)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Neuropsychiatric Disorders Treatment Market, By Formulation Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Immediate release
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Extended release or controlled release
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Long-acting depot formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Orally disintegrating formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Liquid oral formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Prodrug formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Neuropsychiatric Disorders Treatment Market, By Patient Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Adolescent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Adult/Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Neuropsychiatric Disorders Treatment Market, By Care Setting, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Inpatient
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Outpatient
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Community-based Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Home-based Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Telehealth and Virtual Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Neuropsychiatric Disorders Treatment Market, By Provider Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Psychiatrists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Neurologists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Primary Care Physicians
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Psychologists and Therapists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Addiction Medicine Specialists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Integrated Care Teams
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Neuropsychiatric Disorders Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

13. Global Neuropsychiatric Disorders Treatment Market, By Payment Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

14. Global Neuropsychiatric Disorders Treatment Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

15. Competitive Landscape

Johnson and Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Otsuka Holdings Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc (including Allergan)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biogen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Janssen Pharmaceutical Companies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies